Clinical Trial Update: PASS of Paediatric Patients Initiating Selumetinib

View source ↗

Summary

A post-authorization safety study (PASS) update notes ongoing safety monitoring for pediatric patients initiating selumetinib in Neurofibromatosis Type 1. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Neurofibromatosis Type 1 | Status: ACTIVE_NOT_RECRUITING